{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:12:07Z","timestamp":1790302327346,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003491","name":"Herlev Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase and Ejnar Danielsens Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008208","name":"Chief Physician Johan Boserup and Lise Boserups Scholarship","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008208","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jacc.2024.12.033","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T15:36:46Z","timestamp":1742830606000},"page":"1353-1368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Elevated Remnant and LDL Cholesterol and the Risk of Peripheral Artery Disease"],"prefix":"10.1016","volume":"85","author":[{"given":"Benjamin Nilsson","family":"Wadstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carolina","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Berg","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Davey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.12.033_bib1","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.jacc.2024.12.033_bib2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.12.033_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jacc.2024.12.033_bib4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/heartjnl-2014-306906","article-title":"High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease","volume":"101","author":"Stoekenbroek","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2024.12.033_bib5","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1161\/CIRCULATIONAHA.118.034942","article-title":"Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment","volume":"138","author":"Sliz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.12.033_bib6","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","article-title":"Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence","volume":"138","author":"Aday","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.12.033_bib7","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","article-title":"Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease","volume":"75","author":"Duran","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.12.033_bib8","article-title":"Metabolic biomarker discovery for risk of peripheral artery disease compared with coronary artery disease: lipoprotein and metabolite profiling of 31 657 individuals from 5 prospective cohorts","volume":"10","author":"Tikkanen","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.12.033_bib9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.12.033_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","article-title":"Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo","volume":"15","author":"Toth","year":"2016","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacc.2024.12.033_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138332","article-title":"Effect of ezetimibe on LDL-C lowering and atherogenic lipoprotein profiles in type 2 diabetic patients poorly controlled by statins","volume":"10","author":"Sakamoto","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2024.12.033_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S2213-8587(23)00348-0","article-title":"Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?","volume":"12","author":"Smith","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2024.12.033_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10654-020-00622-7","article-title":"Mendel\u2019s laws, Mendelian randomization and causal inference in observational data: substantive and nomenclatural issues","volume":"35","author":"Davey Smith","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jacc.2024.12.033_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41569-020-00493-1","article-title":"Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development","volume":"18","author":"Holmes","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2024.12.033_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.jacc.2024.12.033_bib16","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00125-023-06016-0","article-title":"Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study","volume":"66","author":"Wadstr\u00f6m","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2024.12.033_bib17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/clinchem\/hvaa290","article-title":"Very low-density lipoprotein cholesterol may mediate a substantial component of the effect of obesity on myocardial infarction risk: the Copenhagen General Population Study","volume":"67","author":"Johansen","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2024.12.033_bib18","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1161\/ATVBAHA.124.321387","article-title":"Impaired renal function with higher remnant cholesterol related to risk of atherosclerotic cardiovascular disease: a cohort study","volume":"44","author":"Elias-Lopez","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2024.12.033_bib19","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0022-2275(20)32417-2","article-title":"Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes","volume":"40","author":"Mahley","year":"1999","journal-title":"J\u00a0Lipid Res"},{"issue":"suppl 1","key":"10.1016\/j.jacc.2024.12.033_bib20","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ihj.2023.11.271","article-title":"CSI clinical practice guidelines for dyslipidemia management: executive summary","volume":"76","author":"Sawhney","year":"2024","journal-title":"Indian Heart J"},{"key":"10.1016\/j.jacc.2024.12.033_bib21","first-page":"390","article-title":"Mexican guidelines in the diagnosis and treatment of dyslipidemias and atherosclerosis. Statement of the Mexican Society of Cardiology","volume":"36","author":"Pav\u00eda","year":"2020","journal-title":"Medicina Interna de M\u00e9xico"},{"key":"10.1016\/j.jacc.2024.12.033_bib22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.12.033_bib23","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.12.033_bib24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2024.12.033_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jclinepi.2015.09.016","article-title":"Million Veteran Program: a mega-biobank to study genetic influences on health and disease","volume":"70","author":"Gaziano","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jacc.2024.12.033_bib26","first-page":"1121","article-title":"A\u00a0comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2024.12.033_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2024.12.033_bib29","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/nprot.2010.116","article-title":"Data quality control in genetic case-control association studies","volume":"5","author":"Anderson","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jacc.2024.12.033_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41597-023-01949-y","article-title":"Quality control and removal of technical variation of NMR metabolic biomarker data in \u223c120,000 UK Biobank participants","volume":"10","author":"Ritchie","year":"2023","journal-title":"Sci Data"},{"key":"10.1016\/j.jacc.2024.12.033_bib31","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41591-019-0492-5","article-title":"Genome-wide association study of peripheral artery disease in the Million Veteran Program","volume":"25","author":"Klarin","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.12.033_bib32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41588-020-0640-3","article-title":"Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases","volume":"52","author":"Ishigaki","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2024.12.033_bib33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/CIRCRESAHA.117.312086","article-title":"Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease","volume":"122","author":"van der Harst","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2024.12.033_bib34","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/s41591-022-01891-3","article-title":"Large-scale genome-wide association study of coronary artery disease in genetically diverse populations","volume":"28","author":"Tcheandjieu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.12.033_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2024.12.033_bib36","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/s41588-018-0222-9","article-title":"Genetics of blood lipids among \u223c300,000 multi-ethnic participants of the Million Veteran Program","volume":"50","author":"Klarin","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2024.12.033_bib37","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/ATVBAHA.123.320175","article-title":"Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apoB: a cohort study","volume":"44","author":"Wadstr\u00f6m","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2024.12.033_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010596","article-title":"Strategies to investigate and mitigate collider bias in genetic and Mendelian randomisation studies of disease progression","volume":"19","author":"Mitchell","year":"2023","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jacc.2024.12.033_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001547","article-title":"Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation","volume":"20","author":"Richardson","year":"2022","journal-title":"PLoS Biol"},{"key":"10.1016\/j.jacc.2024.12.033_bib40","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.jacc.2024.12.033_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/ije\/dyy262","article-title":"An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings","volume":"48","author":"Sanderson","year":"2019","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacc.2024.12.033_bib42","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41588-021-00870-7","article-title":"Computationally efficient whole-genome regression for quantitative and binary traits","volume":"53","author":"Mbatchou","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2024.12.033_bib43","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1002\/sim.9133","article-title":"Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization","volume":"40","author":"Sanderson","year":"2021","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2024.12.033_bib44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2024.12.033_bib45","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.12.033_bib46","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.12.033_bib47","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jacc.2018.08.002","article-title":"Pathology of peripheral artery disease in patients with critical limb ischemia","volume":"72","author":"Narula","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.12.033_bib48","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.12.033_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0021-9150(92)90015-9","article-title":"Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency","volume":"95","author":"Mitropoulos","year":"1992","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2024.12.033_bib50","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.ATV.16.11.1333","article-title":"In\u00a0vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway","volume":"16","author":"Silveira","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2024.12.033_bib51","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/01.ATV.14.2.214","article-title":"Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration","volume":"14","author":"Mitropoulos","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2024.12.033_bib52","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1161\/CIRCULATIONAHA.109.918417","article-title":"Inflammation in peripheral artery disease","volume":"122","author":"Brevetti","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.12.033_bib53","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1161\/CIRCRESAHA.121.318327","article-title":"Genetic determinants of peripheral artery disease","volume":"128","author":"Klarin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2024.12.033_bib54","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/ATVBAHA.119.313847","article-title":"Mendelian randomization analysis of hemostatic factors and their contribution to peripheral artery disease\u2014brief report","volume":"41","author":"Small","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2024.12.033_bib55","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.12.033_bib56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12933-023-01927-z","article-title":"Causal associations of remnant cholesterol with cardiometabolic diseases and risk factors: a Mendelian randomization analysis","volume":"22","author":"Guan","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2024.12.033_bib57","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/CIRCULATIONAHA.121.053797","article-title":"Prioritizing the role of major lipoproteins and subfractions as risk factors for peripheral artery disease","volume":"144","author":"Levin","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.12.033_bib58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jacl.2019.12.006","article-title":"Triglycerides, hypertension, and smoking predict cardiovascular disease in dysbetalipoproteinemia","volume":"14","author":"Paquette","year":"2020","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2024.12.033_bib59","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","article-title":"Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study)","volume":"36","author":"Perez de Isla","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2024.12.033_bib60","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.12.033_bib61","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.12.033_bib62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.12.033_bib63","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.12.033_bib64","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725003195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725003195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:33:13Z","timestamp":1775021593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725003195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0735109725003195"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.12.033","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated Remnant and LDL Cholesterol and the Risk of Peripheral Artery Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}